Drug Trial Radar · NCT07512427
Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 24, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
Conditions
- MASH
Interventions
OPK-88006Drug
Administered by subcutaneous injection
PlaceboDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD - OPK-88006 maximum plasma concentration (Cmax)Time frame: 2 hours to 1 week
- SAD - OPK-88006 Time to peak (Tmax)Time frame: 2 hours to 1 week
- SAD - OPK-88006 Elimination half-life (T1/2)Time frame: 10 hours to 200 hours
- SAD - Frequency of treatment emergent adverse events (TEAE)Time frame: Up to 2 weeks
- MAD - Frequency of treatment emergent adverse events (TEAE)Time frame: Up to 20 weeks
- MAD - Change in body weightTime frame: Up to 17 weeks
- MAD - Change in fasting lipidsTime frame: Up to 17 weeks
- MAD - Change in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)Time frame: Up to 17 weeks
- MAD - Change in liver stiffness with Vibration-controlled Transient Elastography (VCTE)Time frame: Up to 17 weeks
- MAD - Change in fibrosis markers measured by Enhanced Liver Fibrosis (ELF) scoreTime frame: Up to 17 weeks
- MAD - Change in hepatic fat measured by MRI-PDFFTime frame: Up to 17 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OPKO study site
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.